Inhibitors of the JAK family of nonreceptor tyrosine kinases have demonstrated clinical efficacy in rheumatoid arthritis and other inflammatory disorders; however, the precise mechanisms by which JAK inhibition improves inflammatory immune responses remain unclear. In this study, we examined the mode of action of tofacitinib (CP-690,550) on JAK/STAT signaling pathways involved in adaptive and innate immune responses. To determine the extent of inhibition of specific JAK/STAT-dependent pathways, we analyzed cytokine stimulation of mouse and human T cells in vitro. We also investigated the consequences of CP-690,550 treatment on Th cell differentiation of naive murine CD4+ T cells. CP-690,550 inhibited IL-4–dependent Th2 cell differentiation and interestingly also interfered with Th17 cell differentiation. Expression of IL-23 receptor and the Th17 cytokines IL-17A, IL-17F, and IL-22 were blocked when naive Th cells were stimulated with IL-6 and IL-23. In contrast, IL-17A production was enhanced when Th17 cells were differentiated in the presence of TGF-β. Moreover, CP-690,550 also prevented the activation of STAT1, induction of T-bet, and subsequent generation of Th1 cells. In a model of established arthritis, CP-690,550 rapidly improved disease by inhibiting the production of inflammatory mediators and suppressing STAT1-dependent genes in joint tissue. Furthermore, efficacy in this disease model correlated with the inhibition of both JAK1 and JAK3 signaling pathways. CP-690,550 also modulated innate responses to LPS in vivo through a mechanism likely involving the inhibition of STAT1 signaling. Thus, CP-690,550 may improve autoimmune diseases and prevent transplant rejection by suppressing the differentiation of pathogenic Th1 and Th17 cells as well as innate immune cell signaling.
Cytokines are key mediators of the development and homeostasis of hematopoietic cells, playing crucial roles in controlling both innate and adaptive immunity (1, 2). Type I and II cytokine receptors represent a structurally distinct class of integral membrane proteins that lack intrinsic enzymatic activity and associate with a family of cytoplasmic protein tyrosine kinases known as JAKs. Upon cytokine-induced activation, JAKs phosphorylate the cytoplasmic tail of the receptor, leading to the recruitment of STATs, which also are phosphorylated by JAKs (3). Activated STATs dimerize, translocate to the nucleus, and regulate the expression of numerous genes (4). The vital role of JAK signaling is illustrated best by the circumstances where these kinases are mutated or deleted (5, 6). For instance, although germline deletion of either JAK1 or JAK2 is lethal, mutation of JAK3 or TYK2 in humans and mice results in immunodeficiency (7, 8). TYK2 mainly transmits the signals derived from type I IFNs and the IL-12 receptor β1 subunit sharing receptors for IL-12 and IL-23 (9), whereas JAK3 has a more discrete function and associates only with the IL-2 receptor common γ chain (γc) shared by the receptors for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 (2). Deficiency of JAK1 leads to nonresponsiveness to type I and type II IFNs, γc cytokines, and gp130 subunit-utilizing cytokines (10), whereas JAK2-deficient cells fail to respond to hormone-like cytokines, such as erythropoietin, thrombopoietin, and GM-CSF (11).
JAKs play a critical role in mediating inflammatory immune responses, and their pharmacological modulation represents a novel approach to the treatment of inflammatory immune-mediated diseases. Indeed, the JAK/STAT pathway has gained significant attention as a therapeutic target in inflammation, autoimmune disease, hematopoietic disorders, and transplant rejection (12, 13). Several small molecule JAK inhibitors have been developed and are currently under clinical investigation (14–17). Tofacitinib (CP-690,550, formerly tasocitinib) is a selective inhibitor of the JAK family with nanomolar potency and a high degree of kinome selectivity (18–20). In cellular assays, it has demonstrated potent inhibition of γc cytokine signaling by blocking IL-2–driven T cell proliferation and functional selectivity over JAK2-dependent GM-CSF–driven proliferation of HUO3 cells (18). More recently, CP-690,550 has been shown to potently inhibit both JAK3- and JAK1-dependent STAT activation with selectivity over JAK2-mediated pathways (21). Results from a phase II trial of oral CP-690,550 as a monotherapy in patients with rheumatoid arthritis (RA) showed efficacy, with 70–80% of patients achieving 20% improvement in the American College of Rheumatology criteria and an acceptable safety profile (22). CP-690,550 is being evaluated currently in phase III trials in RA and other immune-mediated diseases, including psoriasis, Crohn’s disease, and organ transplant rejection (15, 23) (ClinicalTrials.gov [http://clinicaltrials.gov/] NCT00615199). Other JAK inhibitors being studied in the setting of autoimmune disease include the JAK3 inhibitors VX-509 and WYE-151650, the JAK1/JAK2 inhibitors INCB028050 and INCB018424, and the JAK3/Spleen tyrosine kinase inhibitor R348 (12, 13, 17, 24, 25) (ClinicalTrials.gov identifiers NCT00902486, NCT00550043, and NCT00789126).
Because CP-690,550 and the other inhibitors of this class target more than one JAK, their exact mode of action in the setting of inflammatory disease has not been resolved. Autoimmune diseases can be driven by CD4+ T cells that produce IFN-γ (Th1 cells), IL-17 (Th17 cells), or combinations of the two (26). The inflammatory response is supported by innate immune mechanisms that are also particularly relevant in autoimmunity (27). To begin to clarify the mechanism of JAK inhibition vis-à-vis the cognate cytokines that are blocked, we revisited the effects of CP-690,550 on adaptive and innate immune responses.
Materials and Methods
DBA/1J and C57BL/6J mice were purchased from The Jackson Laboratory (Bar Harbor, ME), and STAT1-deficient mice and littermate controls on a 129S6/SvEv background were purchased from Taconic (Hudson, NY). Use of the animals in these studies was reviewed and approved by the Pfizer Institutional Animal Care and Use Committee or by the Institutional Animal Care and Use Committee of the National Institute of Arthritis and Musculoskeletal and Skin Diseases. The animal care and use program at Pfizer is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. Experiments were performed according to the National Institutes of Health guidelines for the use of live animals.
CP-690,550 was prepared by Pfizer Research Laboratories or by the National Institutes of Health Chemical Genomics Center and resuspended in 0.5% methylcellulose/0.025% Tween 20 (Sigma-Aldrich, St. Louis, MO) for in vivo studies or in DMSO for in vitro use.
T cell purification and differentiation
CD4+ T cells were purified by negative selection from spleens and lymph nodes of C57BL/6J and STAT1-deficient or wild-type 129S6/SvEv mice using magnetic cell separation technology (Miltenyi Biotec, Auburn, CA), and the naive CD4+CD62L+CD44+CD25−+
Mouse arthritis model and LPS model
DBA/1J mice were immunized s.c. with 50 μg of chicken type II collagen (Western Institute for Biomedical Research, Salt Lake City, UT) emulsified in CFA (Sigma-Aldrich) and boosted 21 d later with 50 μg of the same Ag in IFA (Sigma-Aldrich). In therapeutic efficacy studies, disease was monitored beginning on day 45, and severity was scored on a scale of 0–3 for each paw, as described previously (28). Mice were sorted into groups of equivalent severity and dosed orally twice daily with vehicle or 50 mg/kg CP-690,550 beginning on day 48. For protein and gene expression analyses, groups of mice were bled by cardiac puncture and euthanized, and both hind paws were excised and flash-frozen 4 h post-treatment on days 48, 49, 52, and 55. For histopathology and immunohistochemistry (IHC) analyses, fore and rear paws were harvested 4 and 12 h post-treatment on day 48 and 4 h post-treatment on days 49 and 55 and fixed in 10% neutral buffered formalin. In studies used to correlate JAK inhibition with efficacy, mice were orally administered vehicle or varying twice daily doses of CP-690,550 on days 22–56, disease was monitored beginning on day 42, and severity was scored as described. Efficacy was determined using the area under the curve of the disease severity time course for each dose.
DBA/1J or C57BL/6J mice were orally administered vehicle or a 5 mg/kg CP-690,550 and 1 h later injected i.p. with 10 μg of Salmonella typhosa LPS (Sigma-Aldrich). Plasma was collected before LPS administration as well as 1, 2, and 6 h after LPS injection.
Plasma cytokine determination
Knockdown of JAK1 and JAK3 with small interfering RNA
Human CD4+ T cells were purified by negative selection from PBMCs using magnetic cell separation technology. Cells were transfected with 1.4 μM SMARTpool small interfering RNA (siRNA) for human JAK1 or JAK3 (Dharmacon, Lafayette, CO) or with a scrambled control using Nucleofector technology (Lonza). Transfected cells were stimulated with 100 ng/ml IL-6 or IL-7 for 15 min, and STAT phosphorylation was assessed by intracellular flow cytometry, as described below.
RNA isolation and gene expression
For cultured T cells, total RNA was isolated using the mir
Freshly isolated CD4+
STAT phosphorylation in whole blood
+ T cells; however, in mice, IL-15– and IL-6–driven STAT activation was examined within CD8+ T cells, because that subpopulation reproducibly yielded greater signal for quantitative evaluation of inhibition. Alexa Fluor 647 geometric mean channel fluorescence derived from gated populations was used to determine the percentage of control stimulation by comparison of compound-treated and vehicle-treated animals. Plasma from each sample was collected, and CP-690,550 concentration was determined by liquid chromatography/mass spectroscopy.
Histopathology and IHC
Fixed paws were decalcified in Immunocal (Decal Chemical, Tallman, NY) for 7 d and paraffin-embedded. To assess general inflammation, 4-μm sections were stained with H&E, independently examined by two board-certified veterinary pathologists (T.P.L. and Z.A.R.), and scored semiquantitatively, as described previously (2930).
CP-690,550 disrupts γc cytokine signaling in CD4+ Th cells
CP-690,550 was designed originally as a JAK3 inhibitor and therefore was expected to interfere with γc cytokine signaling. As shown in Fig. 1A, IL-2 induced the phosphorylation of STAT5 and AKT, and CP-690,550 inhibited both events very effectively. Although it is well established that STATs are JAK substrates, the ability of CP-690,550 to inhibit AKT phosphorylation argues that this pathway is also downstream of JAKs. The CP-690,550–related compound PF-956980 also has been shown to inhibit IL-7–mediated AKT phosphorylation in human thymocytes (31). These results indicate that JAK inhibition interferes with both of the major pathways emanating from cytokine receptors.
IL-21 is a critical immunoregulatory cytokine with important actions on T cells, B cells, and NK cells (32), and it too uses γc (33). As expected, CP-690,550 interfered with IL-21 signaling in mouse CD4+ T cells, as shown by the inhibition of STAT3 and STAT1 phosphorylation (Fig. 1B). We also investigated the ability of CP-690,550 to inhibit γc cytokine signaling in human T cells, and as depicted in Fig. 1C, the inhibitor blocked STAT phosphorylation induced by IL-2, IL-4, IL-7, IL-15, and IL-21 with similar potencies. These results confirmed that CP-690,550 clearly affects signaling pathways downstream of JAK3-dependent γc cytokine receptors in both mouse and human T cells. Because evidence from kinase binding assays has shown that CP-690,550 also can affect JAK family members other than JAK3 (19), we next asked if the inhibitor also interfered with non-γc cytokine receptor signaling in T cells.
CP-690,550 disrupts non-γc cytokine signaling
To investigate the effects of CP-690,550 on JAK3-independent cytokine receptor signaling, we stimulated CD4+ T cells with IL-6, a key inflammatory mediator in CIA and RA (34, 35). IL-6 signaling involves JAK1 in conjunction with JAK2 (2, 10, 11), and in human cells, TYK2 is also a contributor (36, 37). As depicted in Fig. 2A, CP-690,550 inhibited IL-6–driven phosphorylation of STAT3 and STAT1 in mouse CD4+ T cells. Similar results were obtained in human whole blood T cells (Fig. 2B). In both cases, STAT1 phosphorylation was more sensitive to CP-690,550 than STAT3 phosphorylation. To further examine the role that particular JAK family members might play in STAT activation, we used RNA interference (Fig. 2C). Interestingly, inhibiting JAK1 expression in human CD4+ T cells completely suppressed IL-6–mediated STAT1 phosphorylation but had only a partial effect on STAT3 phosphorylation. In these studies, JAK1 inhibition corresponded to >75% reduction in transcript copy number compared with control siRNA, as assessed by quantitative RT-PCR. JAK1 siRNA also abrogated IL-7–dependent STAT5 phosphorylation. As a control, JAK3 siRNA was included, and although it had no effect on IL-6 signaling, JAK3 knockdown completely suppressed IL-7–mediated STAT5 phosphorylation, as would be expected. These data suggest that at least in T cells both IL-6 activation of STAT1 and γc cytokine activated STAT pathways are critically dependent on JAK1. Using the same approach, we were unsuccessful in our attempts to suppress JAK2 or TYK2 expression using RNA interference.
Because CP-690,550 blocked IL-6 signaling, we next studied the effects of JAK inhibition on IFN-γ, a cytokine that also utilizes JAK1 and JAK2. The inhibitor potently blocked the IFN-γ–mediated phosphorylation of STAT1 in CD4+ T cells (Fig. 2D), further confirming that this inhibitor targets not only JAK3 but also JAK1 and/or JAK2. We then considered the possibility that CP-690,550 might also interfere with IL-12 signaling, which is dependent on JAK2 and TYK2. As shown in Fig. 2E, CP-690,550 blocked IL-12–driven phosphorylation of STAT1 but showed only modest suppression of STAT4 activation. Thus, CP-690,550 evidently interferes with multiple JAKs and hence multiple cytokine signaling pathways in T cells. Given these effects on lineage-promoting cytokine signaling, we considered the possibility that this JAK inhibitor also would affect the differentiation of Th cells to various fates.
CP-690,550 blocks the differentiation of Th2 and Th1 cells
Differentiation of Th2 cells is mediated by IL-4, a γc cytokine that signals through JAK3 and JAK1. We therefore expected that CP-690,550 would effectively antagonize Th2 specification. Activating naive Th cells with IL-4 and anti-CD3/anti-CD28 mAb effectively generated GATA3 in cells that expressed high levels of IL-13 (Fig. 3A, 3B). As expected, the expression of GATA3 and Th2 cytokines was inhibited by CP-690,550. However, the TCR-mediated proliferation of Th cells was not affected. IL-2 production was enhanced, consistent with the recognized ability of IL-2 to limit its own production in Th2 and Th1 cells by activating STAT5 (38). It should be noted that adding a strong TCR stimulus (i.e., anti-CD3/anti-CD28) generates cells that produce little IL-4 protein (39). IL-4 mRNA expression was readily detectable in Th2 cells and abolished in the presence of CP-690,550 (data not shown). These findings are consistent with the efficacy of CP-690,550 in preclinical models of Th2-mediated allergic disease (40).
Whereas Th2 cells are nonpathogenic in experimental autoimmune models like CIA, IFN-γ–producing Th1 cells and IL-17–producing Th17 cells have been reported to be responsible for destructive arthritis in mice and humans (41). Therefore, we next studied the effects of CP-690,550 on Th1 cell differentiation. The inhibitor potently suppressed the expression of T-bet and the differentiation of IFN-γ–producing Th1 cells without suppressing cell proliferation (Fig. 3A, 3C). As in Th2 cells, CP-690,550 also enhanced IL-2 production in Th1 cells. Th1 specification is initiated by IL-12 and STAT4 activation; however, IFN-γ amplifies T-bet and IFN-γ expression in Th1 cells through STAT1 activation (42). Of note, the inhibition of T-bet and IFN-γ expression by CP-690,550 was to the same extent as that seen with IFN-γ neutralizing Ab or STAT1-deficient T cells (Fig. 3D). In view of these data and that presented in Fig. 2D and 2E, we would argue that the primary mechanism by which CP-690,550 appears to inhibit Th1 differentiation is through the inhibition of IFN-γ– and IL-12–mediated STAT1 signaling.
CP-690,550 inhibits the generation of IL-23–dependent Th17 cells
Although Th1 cells were thought originally to be the major mediators of immunopathogenesis, it now is recognized increasingly that Th17 cells are also important drivers of autoimmunity (41, 43, 44). Extensive work indicates that cells that selectively produce IL-17A but not other cytokines can arise from naive CD4+ T cells in response to specific cytokine stimulation (45). IL-23 was thought initially to be important for driving Th17 differentiation; however, it was argued later that IL-6 in conjunction with TGF-β was responsible for the initial specification of mouse Th17 cells (46–48). In human cells, the requirement for TGF-β has been less clear, and lately the necessity for TGF-β in mouse has been called into question (49, 50). We have shown recently that Th17 cells can be generated from naive T cells in the absence of TGF-β signaling when using IL-23, IL-1β, and IL-6 (51). Such IL-23–induced Th17 cells express a distinct repertoire of transcription factors, receptors, and mediators and are more pathogenic in vivo. Because IL-2 and IFN-γ inhibit Th17 differentiation (45, 52), it was difficult to predict what the effect of CP-690,550 treatment might be on this lineage. We first polarized cells in the conventional manner, using TGF-β1 and IL-6. Under these conditions, the addition of CP-690,550 enhanced IL-17A and IL-2 production (Fig. 4A, top row), consistent with the ability of the inhibitor to block feedback inhibition mediated by IL-2 (38, 52). Addition of anti–IL-2 had a similar effect to that of the inhibitor (data not shown). Interestingly, the IL-17A–inducing effect of CP-690,550 on Th17 differentiation was strictly dependent on the presence of TGF-β1, because neutralizing the biologic activity of this cytokine abolished IL-17A production (Fig. 4A, 4B).
IL-17A–producing cells generated by TGF-β1 and IL-6 can produce the anti-inflammatory cytokine IL-10 and are less pathogenic upon adoptive transfer than those generated in the presence of IL-23 (53). We also have shown recently that IL-17A–producing cells generated in the absence of TGF-β1 are more pathogenic than those generated in the presence of this immunoregulatory cytokine (51). We therefore examined the effects of CP-690,550 on Th17 cells induced in the absence of TGF-β and found that in sharp contrast to its effects on IL-17A production induced by IL-6 and TGF-β1 the JAK inhibitor dramatically suppressed the differentiation of Th17 cells generated with IL-6 and IL-23 (Fig. 4A, 4B). Under these conditions, neutralizing TGF-β1 did not affect the action of CP-690,550. In contrast, when TGF-β1 was added to the IL-6/IL-23 condition, the JAK inhibitor enhanced IL-17A expression (Fig. 4B). Interestingly, Rorc expression was inhibited in all of the conditions in the presence of CP-690,550, even if increased IL-17A expression was observed (Fig. 4C). CP-690,550 also blocked the expression of Ahr, which is induced primarily in the presence of TGF-β1 (51). As shown previously, Il23r expression was induced dramatically by IL-6 and IL-23 in the absence of TGF-β1 (51). Importantly, CP-690,550 completely abrogated the expression of IL-23R, which strictly depends on STAT3 activation (51) (Fig. 4C).
As shown previously, Th17 cells generated with IL-6, IL-1β, and either TGF-β1 or IL-23 produce not only IL-17A but also IL-17F and IL-22, all of which can contribute to the pathogenicity of these cells (51). As shown in Fig. 5A, CP-690,550 effectively blocked the expression of IL-17A, IL-17F, and IL-22 when Th17 cells were generated in the absence of TGF-β1. In contrast, the JAK inhibitor did not affect IL-17A or IL-17F expression when Th17 cells were induced in the presence of TGF-β1, but IL-22 production was affected. IL-21 is another key cytokine produced by both Th17 cells and follicular Th cells. Of note, its production was blocked efficiently by CP-690,550 regardless of how the Th17 cells were generated (Fig. 5B).
Increasingly, it has been recognized that Th cells that arise in the setting of autoimmunity can produce both IL-17A and IFN-γ; this particularly in human IL-17–producing cells (54, 55). Similarly, T cells found at sites of autoimmune lesions express both Rorγt and T-bet (55). Importantly, Th17 cells generated in the absence of TGF-β also express both Rorγt and T-bet (51), and CP-690,550 blocked T-bet expression in these cells (Fig. 5C). Thus, although CP-690,550 can enhance IL-17 production in TGF-β1–induced Th17 cells, it suppresses IL-17 production in pathogenic IL-23–induced Th17 cells and also inhibits expression of Rorγt, T-bet, and IL-23R.
CP-690,550 rapidly suppresses CIA, inflammatory biomarkers, and STAT1-dependent gene expression
Therapies that selectively target T cell activation or differentiation can block CIA when used prophylactically during immunization but may be less effective in established disease where innate immune mechanisms are also prominent (56). The efficacy of anti-TNF therapies in RA further underscores the role of innate cells in chronic arthritis. Therefore, we examined whether CP-690,550 could influence the course of established arthritis. Mice that had developed symptoms of arthritis by day 45 after collagen immunization were treated with CP-690,550 beginning on day 48. As shown in Fig. 6A, a significant reduction in arthritis was apparent within 48 h (day 50) of initiating treatment, and mice with continuous inhibitor treatment improved throughout the study. Significant expression of inflammatory mediators was noted in the plasma of vehicle-treated mice on day 48. Strikingly, many of these markers were reduced within 4 h of initial CP-690,550 administration (Fig. 6B), suggesting a surprisingly rapid mode of action. It should be noted that in these studies we were unable to detect IL-17 in plasma. From our experience with the mouse CIA model, IL-17 is more readily detectable earlier in disease progression prior to the development of arthritic symptoms (21). Because CP-690,550 potently suppressed STAT1 activation in T cells in response to IL-6, IFN-γ, and IL-12, we sought to determine if the inhibitor also would reduce the expression of canonical STAT1 target genes (57). Interestingly, the prominent expression of many STAT1-responsive genes was evident in mice with arthritis, and the expression of these genes was suppressed rapidly by CP-690,550, as measured in the inflamed joints (Fig. 6C). Continuous CP-690,550 treatment further suppressed the expression of STAT1-responsive genes to near normal levels as disease resolved (data not shown).
To ensure that the observed transcript suppression was not the result of alterations of tissue-infiltrating cells, we examined the inflammatory infiltration in paw tissues from mice treated by the same regimen. As shown in Fig. 6D using histopathology as well as macrophage and T cell IHC assessment of joint tissue, there was no decrease in inflammatory cell infiltrates within the first 24 h of CP-690,550 treatment. These results confirmed the rapid suppression of STAT1 signaling pathways and demonstrated that the beneficial effects of JAK inhibition were not due to leukocyte depletion. Consistent with CP-690,550 effects on the arthritis severity score, histopathology and IHC assessment did, however, reveal significantly reduced inflammation after 7 d of treatment (Fig. 6D, 6E).
Efficacy in mouse CIA correlates with inhibition of both JAK1 and JAK3
To assess the relative JAK inhibition by CP-690,550 in vivo, we measured STAT phosphorylation in ex vivo cytokine-stimulated whole blood from mice, which had been treated orally with the inhibitor. For these experiments, IL-6 signaling through STAT1 was used as a measure of JAK1/JAK2 activity, whereas IL-15 and GM-CSF stimulation of STAT5 were used to assess JAK1/JAK3 and JAK2 signaling pathways, respectively. As shown in Fig. 7A, mice administered a single oral dose of CP-690,550 had similar inhibition of JAK1/JAK2 and JAK1/JAK3 pathways and significantly reduced suppression of the JAK2 pathway, confirming that in vivo CP-690,550 administration inhibits cytokine receptor signaling pathways activating STAT1 to a similar extent as γc cytokine signaling pathways.
The same method was used to evaluate CP-690,550 inhibition of γc cytokine and STAT1-dependent signaling pathways in the context of inflammatory disease. Cytokine signaling was examined in mice that had been treated orally with various doses of CP-690,550 for 5 wk as treatment for CIA (Fig. 7B), and the results revealed that the inhibition of both JAK1/JAK2 and JAK1/JAK3 pathways correlated with efficacy, although there was little or no inhibition of JAK2 at therapeutic doses. These results suggested that the anti-inflammatory activity of CP-690,550 is mediated by its potent inhibition of both JAK1 and JAK3 activity.
CP-690,550 rapidly blocks innate responses in vivo
The rapid suppression of inflammatory cytokines and STAT1-dependent gene expression observed in mice with CIA after CP-690,550 treatment suggested that in addition to suppressing T cell function the JAK inhibitor also might be affecting innate immune responses. To investigate this possibility, we examined the effect of CP-690,550 on the acute response to LPS in vivo, a model known to be dependent upon IFN-γ and STAT1 (58, 59). We found that a single dose of the JAK inhibitor suppressed TNF and IL-6 production along with other inflammatory cytokines (Fig. 7C), confirming a rapid anti-inflammatory mode of action. Interestingly, the production of IL-10 was enhanced by the treatment, consistent with the reported STAT1-mediated repression of this anti-inflammatory cytokine (60). Collectively, these data indicated that the immunosuppressive effects of CP-690,550 appear to be mediated by the blockade of innate as well as adaptive immune responses.
CP-690,550 is being studied currently in a variety of autoimmune diseases. In this study, we show that the inhibitor blocks signaling by JAK3-dependent γc cytokine receptors as well as by other cytokine receptors that signal through JAK1. Accordingly, we found that CP-690,550 interfered with Th1 and Th2 differentiation and also impaired the production of inflammatory Th17 cells generated in response to IL-1β, IL-6, and IL-23. In contrast, the JAK inhibitor enhanced the production of IL-17A in cells cultured with IL-6 and TGF-β1. These effects were associated with the amelioration of murine arthritis, which correlated with the reduced expression of STAT1-dependent genes. Furthermore, CP-690,550 also suppressed cytokine production in a sepsis model, suggesting that the mechanism of action of this drug involves blocking the action of cytokines during innate and adaptive responses.
Despite its advanced stage of clinical development, the mode of action by which CP-690,550 exerts efficacy in RA and other autoimmune settings remains unresolved (15, 22, 23). In contrast to its activity against isolated kinases, CP-690,550 demonstrates functional specificity for JAK1 and JAK3 over other JAK family members in cells, although the basis of this apparent discrepancy has not been determined (18, 21). Because many of the cytokines involved in RA and other autoimmune diseases signal through receptors associated with JAKs, the question arises as to how the effects of CP-690,550 relate to the apparent efficacy of the drug in the setting of autoimmune disease. A central component of the pathophysiology of RA and psoriasis is the action of autoreactive T cells and the inflammatory cytokines that act upon them (61–63). As was expected, CP-690,550 potently inhibited γc cytokine signaling pathways in the current studies by targeting JAK1 and JAK3 in T cells. Similar results have been observed in JAK1- and JAK3-deficient cells (2, 10) and with JAK1-selective inhibitors (M.I. Jesson, unpublished observations), suggesting that the blockade of either or both of these kinases can modulate γc cytokine receptor signals. A recent study also has demonstrated that a selective JAK3 inhibitor, WYE-151650, is effective in CIA (24).
Neither the clinical efficacy of CP-690,550 nor the potential efficacy of other JAK inhibitors is likely to be explained by the inhibition of γc cytokine receptor signaling alone. By such a mechanism, the differentiation of naive T cells to Th2 effector cells would be inhibited, but Th2 cells are likely not relevant to the pathogenesis of CIA in mice or RA and psoriasis in humans (41, 62). Surprisingly, CP-690,550 also prevented Th1 differentiation. Although previous observations have indicated that cellular JAK3 deficiency or inhibition of JAK3 can suppress Th1 differentiation (64), our data suggest a different mechanism, because CP-690,550 suppressed the expression of the Th1-associated transcription factor T-bet. Th1 differentiation is driven by IL-12 and IFN-γ and by the activation of STAT1 and T-bet (42, 65). Our results indicate that CP-690,550 has only a modest effect on IL-12–induced STAT4 activation while profoundly inhibiting STAT1 activation in T cells induced by either IL-12 or IFN-γ. Indeed, the inhibition of IFN-γ signaling alone likely could account for the observed Th1 suppression as demonstrated by the effect of anti–IFN-γ neutralizing Abs. The consequences of CP-690,550 treatment on Th1 differentiation and STAT1 signaling also could explain the efficacy of the inhibitor in a mouse graft-versus-host disease model, where Th1 responses were limited by CP-690,550 without affecting cell proliferation (66).
Although blocking Th1 responses can be highly efficient in graft-versus-host disease and transplant rejection, this mechanism alone likely would be less successful in autoimmune diseases in which Th17 cells also play a major role. Thus, using inhibitors that target not only JAK3 but also JAK1 or JAK2 and subsequently affect the differentiation of Th1 as well as Th17 cells could be of benefit in autoimmune settings. The generation of Th17 cells is regulated by multiple factors. Although IL-6 and TGF-β1 can efficiently induce IL-17 production, IL-6 together with IL-23 and IL-1β, in the absence of TGF-β1, also can induce IL-17 in naive Th cells (50, 51, 67). Indeed, we have shown recently that Th17 cells generated in the absence of TGF-β are more pathogenic in vivo than those generated in the presence of this cytokine (51). Moreover, we have found that the balance between STAT3 and STAT5 activation can have opposing regulatory effects on IL-17 expression (68). Results from the present studies demonstrate that CP-690,550, most likely by inhibiting STAT5, increases IL-17 expression when Th17 cells are generated with TGF-β and IL-6. In contrast, in the absence of TGF-β signaling, CP-690,550 blocked IL-17 expression.
Although the regulation of IL-17A and IL-17F expression is more complex (68), the expression of IL-23R and IL-22 are strictly dependent on STAT3 activation (51). We show in these studies that CP-690,550 interferes with IL-23 action by blocking the upregulation of its receptor and subsequent IL-17 induction. Moreover, CP-690,550 inhibited IL-23R expression under either Th17 condition. Similarly, the JAK inhibitor abrogated STAT3-mediated IL-22 and IL-21 expression in Th17 cells and also inhibited RORγt and T-bet expression. Thus, CP-690,550 potently suppresses the generation of pathogenic Th17 cells with an IL-23/STAT3 signature. Inhibitory effects on Th17-associated cytokines also have been suggested for the JAK1/JAK2 inhibitor INCB028050 (25).
This mode of action of CP-690,550 may be of interest in a number of autoimmune diseases where interfering with IL-23 signaling attenuates disease (41, 69–72). Thus, it may very well be that a clinically important action of CP-690,550 is to block the combined actions of IL-23.
In contrast, IL-6 has wide-ranging biological activities in various target cells. In addition to promoting Th17 differentiation, it regulates immune responses, the acute phase reaction, hematopoiesis, and bone metabolism (73, 74). IL-6–deficient mice are protected from experimental autoimmune diseases such as CIA (34). Additionally, elevated serum IL-6 levels have been observed in patients with inflammatory diseases such as RA and Crohn’s disease, and tocilizumab, a humanized anti–IL-6R Ab that blocks IL-6 signaling, has shown clinical efficacy in these indications, ameliorating inflammation and normalizing acute phase protein levels (75). Our data indicate that CP-690,550 interferes with the production of IL-6 and also blocks IL-6 signaling, which could be explained by the effects of the inhibitor on JAK1 and/or JAK2. Thus, an additional mechanism underlying CP-690,550 efficacy in RA is likely mediated through effects on IL-6.
We were surprised by the rapid effects of CP-690,550 on established disease in the mouse CIA model. Indeed, effects of the inhibitor were observable within hours of initiating treatment. Despite the inhibitory consequences of CP-690,550 on Th cell differentiation, it seemed unlikely that this could induce such rapid effects in vivo. Rather, the rapid suppression of inflammatory responses suggested that the blockade of innate immune mechanisms might represent part of the salutatory effects of JAK inhibition. This led us to examine the efficacy of the JAK inhibitor in the sepsis model. Importantly, we found that CP-690,550 had no direct effect on TLR4 signaling in vitro, because we did not observe the inhibition of LPS-induced TNF or IL-6 production from human PBMCs (data not shown). Rather, the suppression of acute TNF responses in vivo after LPS administration is more consistent with the inhibition of IFN-γ signaling by the blockade of JAK1, because both STAT1-deficient and IFN-γR–deficient mice are resistant to LPS-induced endotoxemic shock (58, 59,). In contrast, IFN-γ priming of macrophages has been shown to enhance both LPS-stimulated TNF production in vivo (76) and STAT1 expression (77), and it has been suggested that IFN-γ activation of STAT1 may alter signaling pathways downstream of anti-inflammatory cytokines such as IL-10 or TGF-β, leading to antagonism of their suppressive function (78). If this were the case, then CP-690,550 suppression of STAT1-responsive genes could override the effect of priming. IL-10 responses to LPS are enhanced in mice made deficient for IFN-α/β/γ or STAT1 (60), suggesting that STAT1 is a negative regulator of IL-10 gene expression. Our observations were consistent with this hypothesis, because we observed enhanced IL-10 levels in LPS-treated mice given the JAK inhibitor. Another possible contribution to CP-690,550 suppression of LPS responses in vivo could involve the blockade of IL-15 signaling, because both IL-15 deficiency and anti–IL-15 neutralizing Ab have been shown to suppress LPS-induced endotoxemia in vivo (79). Although there is no doubt that IL-15 signaling is inhibited potently by CP-690,550, this mechanism cannot explain completely the results from the current study, because the blockade of IL-15 signaling would not be expected to affect IL-10 in this model.
The simultaneous control of signaling pathways involved in innate and adaptive immune responses by CP-690,550 may explain why this JAK inhibitor has produced rapid clinical improvement in RA patients who previously have failed other disease-modifying antirheumatic drug therapies or TNF antagonists (22). On the basis of the present data, it appears that the efficacy of CP-690,550 is likely based on its ability to block multiple cytokines and break the cycle of inflammation. Clearly, it will be important to try to understand which critical cytokines are blocked in humans undergoing JAK inhibitor treatment and the extent to which signaling is abrogated. As such, our findings have implications for the possible utility of CP-690,550 in a wide variety of inflammatory disorders.
The National Institutes of Health (NIH) has a patent related to JAKs as novel immunomodulatory agents, and J.J.O. and the NIH have a Collaborative Research Agreement and Development Award with Pfizer. M.I.J., C.E.S., T.P.L, Z.A.R., M.E.D., R.D.H., and D.M.M are current Pfizer employees. X.L., J.L.L., S.G., J.W.A., J.D.W., J.C.M., and N.K have been employed by Pfizer within the last 5 years. M.I.J., T.P.L., Z.A.R., M.E.D., R.D.H., D.D.M., and N.K. have stock or equity interests.
This work was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases and Pfizer, Inc.
Abbreviations used in this article:
- common γ chain
- rheumatoid arthritis
- serum amyloid A
- small interfering RNA.
- Received November 3, 2010.
- Accepted February 1, 2011.